HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Refractory hemophagocytic syndrome in systemic lupus erythematosus successfully treated with intermittent intravenous cyclophosphamide: three case reports and literature review.

Abstract
We experienced three patients with refractory or severe hemophagocytic syndrome associated with the activity of systemic lupus erythematosus, so-called acute lupus hemophagocytic syndrome (ALHS). All patients were successfully treated with intermittent intravenous injections of cyclophosphamide (IVCY). In each patient, hemophagocytosis was found during bone marrow examination, and infectious causes of hemophagocytic syndrome were carefully excluded. Patients 1 and 2 were refractory to combination therapy with a high-dose corticosteroid and rituximab or cyclosporine and were successfully treated with additive IVCY. Patient 3 had very severe ALHS that developed after cardiac surgery but was successfully treated with a high-dose corticosteroid and IVCY. We conducted a literature review of adult ALHS and analyzed 54 cases reported from 2006 to 2013. Although the clinical and laboratory features were diverse, fever, bicytopenia or pancytopenia, and hyperferritinemia were almost universal. Including our 3 patients, a total of 16 have reportedly been treated with IVCY-containing regimens, and ALHS was successfully controlled in most of them without switching or adding other therapies. We suggest that combination therapy with IVCY and corticosteroids may be useful to treat severe or refractory ALHS.
AuthorsYo Ueda, Hiroyuki Yamashita, Yuko Takahashi, Hiroshi Kaneko, Toshikazu Kano, Akio Mimori
JournalClinical rheumatology (Clin Rheumatol) Vol. 33 Issue 2 Pg. 281-6 (Feb 2014) ISSN: 1434-9949 [Electronic] Germany
PMID24343456 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Immunosuppressive Agents
  • Rituximab
  • Cyclosporine
  • Cyclophosphamide
Topics
  • Administration, Intravenous
  • Adolescent
  • Adrenal Cortex Hormones (administration & dosage)
  • Adult
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage)
  • Antirheumatic Agents (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Cyclosporine (administration & dosage)
  • Female
  • Humans
  • Immunosuppressive Agents (administration & dosage)
  • Lupus Erythematosus, Systemic (complications, drug therapy)
  • Lymphohistiocytosis, Hemophagocytic (complications, drug therapy)
  • Male
  • Middle Aged
  • Rituximab
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: